167 related articles for article (PubMed ID: 3119213)
1. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
Nakajima H; Izumi Y; Sugihara S; Satoh Y; Isumi S; Gotoh T; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):201-8. PubMed ID: 3119213
[TBL] [Abstract][Full Text] [Related]
2. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
3. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.
Yoshioka T; Fujiwara H; Takai Y; Ogata M; Shimizu J; Hamaoka T
Cancer Immunol Immunother; 1987; 24(1):8-12. PubMed ID: 3493074
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
[TBL] [Abstract][Full Text] [Related]
6. Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF).
De Groot JW; De Weger RA; Vandebriel RJ; Den Otter W
Immunobiology; 1989 Jun; 179(2-3):131-44. PubMed ID: 2676851
[TBL] [Abstract][Full Text] [Related]
7. Mediation of in vivo tumor-neutralizing activity by Lyt-2+ as well as L3T4+ T cell subsets.
Yoshioka T; Sato S; Ogata M; Sakamoto K; Sano H; Shima J; Yamamoto H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jan; 79(1):91-8. PubMed ID: 2965692
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 enhancement of lymphokine secretion by T lymphocytes: analysis of established clones and primary limiting dilution microcultures.
Kelso A; MacDonald HR; Smith KA; Cerottini JC; Brunner KT
J Immunol; 1984 Jun; 132(6):2932-8. PubMed ID: 6233365
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms for recognition of tumor antigens and mediation of anti-tumor effect by noncytolytic Lyt-2+ T cell subset.
Sakamoto K; Yoshioka T; Shimizu J; Sato S; Nakajima H; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1988 Jan; 79(1):99-108. PubMed ID: 3128511
[TBL] [Abstract][Full Text] [Related]
11. Positively selected Lyt-2+ and Lyt-2- mouse T lymphocytes are comparable, after Con A stimulation, in release of IL 2 and of lymphokines acting on B cells, macrophages, and mast cells, but differ in interferon production.
Guerne PA; Piguet PF; Vassalli P
J Immunol; 1983 May; 130(5):2225-30. PubMed ID: 6187845
[TBL] [Abstract][Full Text] [Related]
12. Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor.
Svedersky LP; Benton CV; Berger WH; Rinderknecht E; Harkins RN; Palladino MA
J Exp Med; 1984 Mar; 159(3):812-27. PubMed ID: 6421982
[TBL] [Abstract][Full Text] [Related]
13. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
15. Macrophage activation factor from EL-4, a murine T-cell line: antigenic characterization by hamster monoclonal antibodies to murine interferon-gamma.
Meltzer MS; Gilbreath MJ; Crawford RM; Schreiber RD; Nacy CA
Cell Immunol; 1987 Jul; 107(2):340-7. PubMed ID: 3109744
[TBL] [Abstract][Full Text] [Related]
16. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor effect of PSK (2): effector mechanism of the antimetastatic effect in the "double grafted tumor system"].
Ebina T; Kohya H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1847-53. PubMed ID: 3592718
[TBL] [Abstract][Full Text] [Related]
19. Biological and biochemical characterization of macrophage activating factor (MAF) in murine lymphocytes: physiocochemical similarity of MAF to gamma interferon (IFN-gamma).
Fukazawa Y; Kagaya K; Miura H; Shinoda T; Natori K; Yamazaki S
Microbiol Immunol; 1984; 28(6):691-702. PubMed ID: 6434908
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.
Celada A; Gray PW; Rinderknecht E; Schreiber RD
J Exp Med; 1984 Jul; 160(1):55-74. PubMed ID: 6330272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
